These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 10569737)

  • 1. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.
    Ryan EJ; McNeela E; Murphy GA; Stewart H; O'hagan D; Pizza M; Rappuoli R; Mills KH
    Infect Immun; 1999 Dec; 67(12):6270-80. PubMed ID: 10569737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity.
    Ryan EJ; McNeela E; Pizza M; Rappuoli R; O'Neill L; Mills KH
    J Immunol; 2000 Nov; 165(10):5750-9. PubMed ID: 11067933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative diphtheria, tetanus and whooping cough immunization schedule to evoke a Th2 tetanus and a Th1 pertussis immune response.
    Lavigne MV; Castro M; Andino J; Manghi M
    Microbes Infect; 2004 Apr; 6(5):481-4. PubMed ID: 15109963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal immunization with outer membrane vesicle pertussis vaccine confers broad protection through mucosal IgA and Th17 responses.
    Raeven RHM; Rockx-Brouwer D; Kanojia G; van der Maas L; Bindels THE; Ten Have R; van Riet E; Metz B; Kersten GFA
    Sci Rep; 2020 Apr; 10(1):7396. PubMed ID: 32355188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses.
    Tierney R; Beignon AS; Rappuoli R; Muller S; Sesardic D; Partidos CD
    J Infect Dis; 2003 Sep; 188(5):753-8. PubMed ID: 12934192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bordetella pertussis-specific Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine: comparison of the T cell cytokine profiles in infants and mice.
    Ryan M; Gothefors L; Storsaeter J; Mills KH
    Dev Biol Stand; 1997; 89():297-305. PubMed ID: 9272363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii.
    Bonenfant C; Dimier-Poisson I; Velge-Roussel F; Buzoni-Gatel D; Del Giudice G; Rappuoli R; Bout D
    Infect Immun; 2001 Mar; 69(3):1605-12. PubMed ID: 11179334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-cell Bordetella pertussis vaccine component modulates the mouse immune response to an unrelated soluble antigen.
    Lavigne MV; Castro M; Mateo N; Deluchi S; Atzori C; Piudo L; Calcagno M; Brero ML; Manghi M
    Microbes Infect; 2002 Jul; 4(8):815-20. PubMed ID: 12270728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.
    Boyaka PN; Ohmura M; Fujihashi K; Koga T; Yamamoto M; Kweon MN; Takeda Y; Jackson RJ; Kiyono H; Yuki Y; McGhee JR
    J Immunol; 2003 Jan; 170(1):454-62. PubMed ID: 12496431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal Immunization with Acellular Pertussis Vaccines Results in Long-Term Immunity to Bordetella pertussis in Mice.
    Wolf MA; Boehm DT; DeJong MA; Wong TY; Sen-Kilic E; Hall JM; Blackwood CB; Weaver KL; Kelly CO; Kisamore CA; Bitzer GJ; Bevere JR; Barbier M; Damron FH
    Infect Immun; 2021 Feb; 89(3):. PubMed ID: 33318136
    [No Abstract]   [Full Text] [Related]  

  • 12. A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine.
    Dunne A; Mielke LA; Allen AC; Sutton CE; Higgs R; Cunningham CC; Higgins SC; Mills KH
    Mucosal Immunol; 2015 May; 8(3):607-17. PubMed ID: 25315966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55.
    Neidleman JA; Vajdy M; Ugozzoli M; Ott G; O'Hagan D
    Immunology; 2000 Sep; 101(1):154-60. PubMed ID: 11012767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin.
    Beignon AS; Briand JP; Rappuoli R; Muller S; Partidos CD
    Infect Immun; 2002 Jun; 70(6):3012-9. PubMed ID: 12010992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin.
    Bowe F; Lavelle EC; McNeela EA; Hale C; Clare S; Arico B; Giuliani MM; Rae A; Huett A; Rappuoli R; Dougan G; Mills KH
    Infect Immun; 2004 Jul; 72(7):4052-60. PubMed ID: 15213150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral immunization with the B subunit of the heat-labile enterotoxin of Escherichia coli induces early Th1 and late Th2 cytokine expression in Peyer's patches.
    Nakagawa I; Takahashi I; Kiyono H; McGhee JR; Hamada S
    J Infect Dis; 1996 Jun; 173(6):1428-36. PubMed ID: 8648216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.
    Douce G; Giannelli V; Pizza M; Lewis D; Everest P; Rappuoli R; Dougan G
    Infect Immun; 1999 Sep; 67(9):4400-6. PubMed ID: 10456880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models.
    DeJong MA; Wolf MA; Bitzer GJ; Hall JM; Fitzgerald NA; Pyles GM; Huckaby AB; Petty JE; Lee K; Barbier M; Bevere JR; Ernst RK; Damron FH
    Infect Immun; 2024 Mar; 92(3):e0022323. PubMed ID: 38323817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of a new enhanced tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine against Bordetella pertussis in a murine model.
    Kang KR; Huh DH; Kim JA; Kang JH
    BMC Immunol; 2021 Oct; 22(1):68. PubMed ID: 34641798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.